Compare AVXL & EB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | EB |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.6M | 434.6M |
| IPO Year | N/A | 2018 |
| Metric | AVXL | EB |
|---|---|---|
| Price | $3.64 | $4.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.00 | $5.00 |
| AVG Volume (30 Days) | 2.6M | ★ 2.9M |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $294,798,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.86 | $1.81 |
| 52 Week High | $14.44 | $4.46 |
| Indicator | AVXL | EB |
|---|---|---|
| Relative Strength Index (RSI) | 33.60 | 83.41 |
| Support Level | $3.56 | $2.44 |
| Resistance Level | $4.88 | $4.46 |
| Average True Range (ATR) | 0.31 | 0.01 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 6.06 | 75.00 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.